[LH and GnRH antagonists].
New GnRH antagonists are available in clinical practice. The different studies have confirmed the efficacy of these antagonists in preventing the LH surge. Two protocols have been described: in the multiple dose regimens, small doses of antagonist (0.25 mg) are injected starting on stimulation day 5 or 6 until hCG. In the single dose protocol, one injection of a larger dose (3 mg) is proposed in the late follicular phase. The remaining levels of endogenous LH appears to be sufficient in the multiple doses protocol. In the single an estradiol drop is observed in some patient following the 3 mg injection of Cetrorelix. This drop is related to the LH decrease. Its adverse effect on IVF results is not demonstrated.
Olivennes
F
F
Service de gynécologie obstétrique, Hôpital Antoine-Béclère, Clamart.
D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D010062:Ovulation Induction
D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; C062876:cetrorelix